<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002702</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A1201</org_study_id>
    <nct_id>NCT02002702</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of Serelaxin When Added to Standard Therapy in Japanese Acute Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study to assess safety,
      tolerability and pharmacokinetics and to explore efficacy of IV infusion of 10 µg/kg/day and
      30 µg/kg/day serelaxin for 48 hours compared to placebo, when added to the standard therapy,
      in approximately 45 Japanese AHF patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs and SAEs, AEs Requiring Dose Adjustment or Interruption and Additional Therapy</measure>
    <time_frame>From start of study treatment up to Day 5 (for AEs); From start of study treatment up to Day 14 (for SAEs)</time_frame>
    <description>AEs were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards. AEs leading to discontinuations, or requiring dose adjustment or interruptions and additional therapy were assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Serelaxin</measure>
    <time_frame>Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)</time_frame>
    <description>Maximum plasma concentration (Cmax) was defined as the peak level of serelaxin, derived from plasma concentration-time data, using a non-compartmental model approach.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight Adjusted Clearance (CL) of Serelaxin</measure>
    <time_frame>Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)</time_frame>
    <description>Weight adjusted clearance (CL) was defined as the total body clearance of serelaxin after drug administration. CL was calculated as nominal infusion rate divided by Css, using a non-compartmental model approach.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at Steady-state (Css) of Serelaxin</measure>
    <time_frame>Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)</time_frame>
    <description>Concentration at steady-state (Css) was defined as concentration at the state of equilibrium obtained at the end of a certain number of administrations. Css of serelaxin in plasma was calculated by using a non-compartmental model approach.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area Under the Curve (AUC) for Systolic Blood Pressure (SBP) Through 48 Hours of Infusion at Day 5</measure>
    <time_frame>Baseline, 48 hours, Day 5</time_frame>
    <description>The area under the curve (AUC) was defined as area under the plasma concentration-time curve from time zero to time of the last time point with measurable concentration, calculated by a trapezoidal method. Systolic blood pressure was measured using a calibrated standard sphygmomanometer after the subject remained in sitting position for 3 minutes at clinic during the visit. Sample collected at: Baseline; 30 &amp; 60 minutes and then every hour for the first 6 hours of study drug infusion, and then every 3 hours during 48 hours of study drug infusion; every 3 hours until 12 hours following end of infusion, then every 6 hours for 48 hours and then every 24 hours until the earlier of Day 5 or discharge.
AUC for SBP is standardized by dividing by the length of respective time ranges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aldosterone Levels Through Day 14</measure>
    <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
    <description>Aldosterone biomarker was used to assess the effect of serelaxinin on fluid retention. Geometric means of the ratio of post-Baseline values to baseline values of aldosterone was calculated by treatment for the full analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cystatin-C Levels Through Day 14</measure>
    <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
    <description>Cystatin-C biomarker was used to assess the effect of serelaxinin on worsening of renal function. Geometric means of the ratio of post-Baseline values to baseline values of Cystatin-C was calculated by treatment for the full analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitivity Troponin-T Levels Through Day 14</measure>
    <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
    <description>High sensitivity Troponin-T biomarker was used to assess the effect of serelaxin on myocardial damage. Geometric means of the ratio of post-Baseline values to baseline values of high sensitivity troponin-t was calculated by treatment for the full analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in NT-proBNP Levels Through Day 14</measure>
    <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
    <description>NT-proBNP biomarker was used to assess the effect of serelaxinin on degree of cardiac wall stress and congestion. Geometric means of the ratio of post-Baseline values to baseline values of NT-proBNP was calculated by treatment for the full analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neutrophil Gelatinase-asc Lipocalin (NGAL) Levels Through Day 14</measure>
    <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
    <description>Neutrophil gelatinase-asc lipocalin (NGAL) biomarker was used to assess the effect of serelaxin on kidney function. Geometric means of the ratio of post-Baseline values to baseline values of NGAL was calculated by treatment for the full analysis set.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Serelaxin 10 mcg/kg/Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serelaxin 30 mcg/kg/Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Serelaxin 10 mcg/kg/Day</arm_group_label>
    <arm_group_label>Serelaxin 30 mcg/kg/Day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Written informed consent must be obtained before any study-specific assessment is
             performed.

          -  Male or female ≥20 years of age, with body weight ≥30 kg and ≤160 kg

          -  Hospitalized for AHF; AHF is defined as including all of the followings measured at
             any time between presentation (including the emergency department) and the end of
             screening:

          -  Dyspnea at rest or with minimal exertion

          -  Pulmonary congestion on chest radiograph

          -  BNP ≥350 pg/mL or NT-proBNP ≥1,400 pg/mL

          -  SBP ≥125 mmHg at the start and at the end of screening

          -  Able to be randomized within 16 hours from presentation to the hospital, including the
             emergency department

          -  Received intravenous (IV) furosemide of at least 40 mg (or equivalent) at any time
             between presentation (this include outpatient clinic, ambulance, or hospital including
             emergency department) and the start of screening for the study for the treatment of
             the current acute heart failure (HF) episode.

          -  Impaired renal function defined as an estimated glomerular filtration rate (eGFR)
             between presentation and randomization of ≥ 25 and≤ 75 mL/min/1.73 m2, calculated
             using the Japanese formula

        Key Exclusion Criteria:

          -  Dyspnea primarily due to non-cardiac causes

          -  Temperature &gt;38.5°C (oral or equivalent) or sepsis or active infection requiring IV
             anti-microbial treatment

          -  Clinical evidence of acute coronary syndrome currently or within 30 days prior to
             enrollment.

          -  AHF due to significant arrhythmias, which include any of the following: sustained
             ventricular tachycardia, bradycardia with sustained ventricular rate &lt;45 beats per
             minute, or atrial fibrillation/flutter with sustained ventricular response of &gt;130
             beats per minute.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seto-city</city>
        <state>Aichi</state>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iizuka-city</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hiroshima-city</city>
        <state>Hiroshima</state>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amagasaki-city</city>
        <state>Hyogo</state>
        <zip>660-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Higashiibaraki-gun</city>
        <state>Ibaraki</state>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>981-3107</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ueda-city</city>
        <state>Nagano</state>
        <zip>386-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama-city</city>
        <state>Saitama</state>
        <zip>350-1323</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komatsushima-city</city>
        <state>Tokushima</state>
        <zip>773-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2013</study_first_submitted>
  <study_first_submitted_qc>December 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <results_first_submitted>August 3, 2015</results_first_submitted>
  <results_first_submitted_qc>September 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2015</results_first_posted>
  <last_update_submitted>September 11, 2015</last_update_submitted>
  <last_update_submitted_qc>September 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute heart failure (AHF),</keyword>
  <keyword>Japanese,</keyword>
  <keyword>Safety and tolerability, Pharmacokinetics,</keyword>
  <keyword>Renal Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 15 centers in Japan.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Serelaxin 10 mcg/kg/Day</title>
          <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
        </group>
        <group group_id="P2">
          <title>Serelaxin 30 mcg/kg/Day</title>
          <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis was performed on safety population defined as all randomized participants received any amount of study drug and had at least one post-baseline safety assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Serelaxin 10 mcg/kg/Day</title>
          <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
        </group>
        <group group_id="B2">
          <title>Serelaxin 30 mcg/kg/Day</title>
          <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="11.77"/>
                    <measurement group_id="B2" value="79.7" spread="9.01"/>
                    <measurement group_id="B3" value="76.4" spread="12.08"/>
                    <measurement group_id="B4" value="75.3" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs and SAEs, AEs Requiring Dose Adjustment or Interruption and Additional Therapy</title>
        <description>AEs were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards. AEs leading to discontinuations, or requiring dose adjustment or interruptions and additional therapy were assessed.</description>
        <time_frame>From start of study treatment up to Day 5 (for AEs); From start of study treatment up to Day 14 (for SAEs)</time_frame>
        <population>The analysis was performed on the safety population, defined as all participants who received at least one dose of study treatment and had at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs and SAEs, AEs Requiring Dose Adjustment or Interruption and Additional Therapy</title>
          <description>AEs were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards. AEs leading to discontinuations, or requiring dose adjustment or interruptions and additional therapy were assessed.</description>
          <population>The analysis was performed on the safety population, defined as all participants who received at least one dose of study treatment and had at least one post-baseline assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs requiring dose adjustment or interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs requiring additional therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Serelaxin</title>
        <description>Maximum plasma concentration (Cmax) was defined as the peak level of serelaxin, derived from plasma concentration-time data, using a non-compartmental model approach.</description>
        <time_frame>Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)</time_frame>
        <population>The analysis was performed in the pharmacokinetic (PK) set, defined as all participants who received study treatment and had at least one evaluable PK parameter data. Here, &quot;Number of participants analyzed&quot; signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Serelaxin</title>
          <description>Maximum plasma concentration (Cmax) was defined as the peak level of serelaxin, derived from plasma concentration-time data, using a non-compartmental model approach.</description>
          <population>The analysis was performed in the pharmacokinetic (PK) set, defined as all participants who received study treatment and had at least one evaluable PK parameter data. Here, &quot;Number of participants analyzed&quot; signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.</population>
          <units>nanogram(s)/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" spread="2.07"/>
                    <measurement group_id="O2" value="19.2" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weight Adjusted Clearance (CL) of Serelaxin</title>
        <description>Weight adjusted clearance (CL) was defined as the total body clearance of serelaxin after drug administration. CL was calculated as nominal infusion rate divided by Css, using a non-compartmental model approach.</description>
        <time_frame>Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)</time_frame>
        <population>The analysis was performed in the PK population. Here, &quot;Number of participants analyzed&quot; signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Adjusted Clearance (CL) of Serelaxin</title>
          <description>Weight adjusted clearance (CL) was defined as the total body clearance of serelaxin after drug administration. CL was calculated as nominal infusion rate divided by Css, using a non-compartmental model approach.</description>
          <population>The analysis was performed in the PK population. Here, &quot;Number of participants analyzed&quot; signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.</population>
          <units>mL/hr/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="15.4"/>
                    <measurement group_id="O2" value="70.2" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration at Steady-state (Css) of Serelaxin</title>
        <description>Concentration at steady-state (Css) was defined as concentration at the state of equilibrium obtained at the end of a certain number of administrations. Css of serelaxin in plasma was calculated by using a non-compartmental model approach.</description>
        <time_frame>Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)</time_frame>
        <population>The analysis was performed in the PK population. Here, &quot;Number of participants analyzed&quot; signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at Steady-state (Css) of Serelaxin</title>
          <description>Concentration at steady-state (Css) was defined as concentration at the state of equilibrium obtained at the end of a certain number of administrations. Css of serelaxin in plasma was calculated by using a non-compartmental model approach.</description>
          <population>The analysis was performed in the PK population. Here, &quot;Number of participants analyzed&quot; signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" spread="1.96"/>
                    <measurement group_id="O2" value="19.1" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area Under the Curve (AUC) for Systolic Blood Pressure (SBP) Through 48 Hours of Infusion at Day 5</title>
        <description>The area under the curve (AUC) was defined as area under the plasma concentration-time curve from time zero to time of the last time point with measurable concentration, calculated by a trapezoidal method. Systolic blood pressure was measured using a calibrated standard sphygmomanometer after the subject remained in sitting position for 3 minutes at clinic during the visit. Sample collected at: Baseline; 30 &amp; 60 minutes and then every hour for the first 6 hours of study drug infusion, and then every 3 hours during 48 hours of study drug infusion; every 3 hours until 12 hours following end of infusion, then every 6 hours for 48 hours and then every 24 hours until the earlier of Day 5 or discharge.
AUC for SBP is standardized by dividing by the length of respective time ranges.</description>
        <time_frame>Baseline, 48 hours, Day 5</time_frame>
        <population>The analysis was performed in the full analysis set (FAS) population, defined as all participants who were randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area Under the Curve (AUC) for Systolic Blood Pressure (SBP) Through 48 Hours of Infusion at Day 5</title>
          <description>The area under the curve (AUC) was defined as area under the plasma concentration-time curve from time zero to time of the last time point with measurable concentration, calculated by a trapezoidal method. Systolic blood pressure was measured using a calibrated standard sphygmomanometer after the subject remained in sitting position for 3 minutes at clinic during the visit. Sample collected at: Baseline; 30 &amp; 60 minutes and then every hour for the first 6 hours of study drug infusion, and then every 3 hours during 48 hours of study drug infusion; every 3 hours until 12 hours following end of infusion, then every 6 hours for 48 hours and then every 24 hours until the earlier of Day 5 or discharge.
AUC for SBP is standardized by dividing by the length of respective time ranges.</description>
          <population>The analysis was performed in the full analysis set (FAS) population, defined as all participants who were randomized in the study.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.21" spread="2.903"/>
                    <measurement group_id="O2" value="-18.6" spread="3.018"/>
                    <measurement group_id="O3" value="-10.88" spread="3.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.79" spread="2.761"/>
                    <measurement group_id="O2" value="-22.14" spread="2.871"/>
                    <measurement group_id="O3" value="-14.77" spread="2.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aldosterone Levels Through Day 14</title>
        <description>Aldosterone biomarker was used to assess the effect of serelaxinin on fluid retention. Geometric means of the ratio of post-Baseline values to baseline values of aldosterone was calculated by treatment for the full analysis set.</description>
        <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
        <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aldosterone Levels Through Day 14</title>
          <description>Aldosterone biomarker was used to assess the effect of serelaxinin on fluid retention. Geometric means of the ratio of post-Baseline values to baseline values of aldosterone was calculated by treatment for the full analysis set.</description>
          <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.985" lower_limit="0.7636" upper_limit="1.2717"/>
                    <measurement group_id="O2" value="0.816" lower_limit="0.6118" upper_limit="1.0897"/>
                    <measurement group_id="O3" value="0.791" lower_limit="0.6374" upper_limit="0.9825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.975" lower_limit="0.7492" upper_limit="1.2685"/>
                    <measurement group_id="O2" value="0.721" lower_limit="0.5195" upper_limit="0.9999"/>
                    <measurement group_id="O3" value="0.911" lower_limit="0.7141" upper_limit="1.1620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.895" lower_limit="0.6327" upper_limit="1.2656"/>
                    <measurement group_id="O2" value="0.825" lower_limit="0.6468" upper_limit="1.0531"/>
                    <measurement group_id="O3" value="0.816" lower_limit="0.5352" upper_limit="1.2452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.510" lower_limit="0.9934" upper_limit="2.2962"/>
                    <measurement group_id="O2" value="1.114" lower_limit="0.7983" upper_limit="1.5555"/>
                    <measurement group_id="O3" value="1.179" lower_limit="0.8337" upper_limit="1.6661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cystatin-C Levels Through Day 14</title>
        <description>Cystatin-C biomarker was used to assess the effect of serelaxinin on worsening of renal function. Geometric means of the ratio of post-Baseline values to baseline values of Cystatin-C was calculated by treatment for the full analysis set.</description>
        <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
        <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cystatin-C Levels Through Day 14</title>
          <description>Cystatin-C biomarker was used to assess the effect of serelaxinin on worsening of renal function. Geometric means of the ratio of post-Baseline values to baseline values of Cystatin-C was calculated by treatment for the full analysis set.</description>
          <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.921" lower_limit="0.8863" upper_limit="0.9565"/>
                    <measurement group_id="O2" value="0.988" lower_limit="0.9213" upper_limit="1.0598"/>
                    <measurement group_id="O3" value="0.985" lower_limit="0.9291" upper_limit="1.0450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.930" lower_limit="0.8736" upper_limit="0.9900"/>
                    <measurement group_id="O2" value="0.852" lower_limit="0.6465" upper_limit="1.1236"/>
                    <measurement group_id="O3" value="0.965" lower_limit="0.9002" upper_limit="1.0346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.062" lower_limit="0.9898" upper_limit="1.1384"/>
                    <measurement group_id="O2" value="1.115" lower_limit="1.0207" upper_limit="1.2178"/>
                    <measurement group_id="O3" value="1.038" lower_limit="0.9627" upper_limit="1.1194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.195" lower_limit="1.0154" upper_limit="1.4057"/>
                    <measurement group_id="O2" value="1.136" lower_limit="1.0348" upper_limit="1.2472"/>
                    <measurement group_id="O3" value="1.125" lower_limit="1.0313" upper_limit="1.2271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitivity Troponin-T Levels Through Day 14</title>
        <description>High sensitivity Troponin-T biomarker was used to assess the effect of serelaxin on myocardial damage. Geometric means of the ratio of post-Baseline values to baseline values of high sensitivity troponin-t was calculated by treatment for the full analysis set.</description>
        <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
        <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitivity Troponin-T Levels Through Day 14</title>
          <description>High sensitivity Troponin-T biomarker was used to assess the effect of serelaxin on myocardial damage. Geometric means of the ratio of post-Baseline values to baseline values of high sensitivity troponin-t was calculated by treatment for the full analysis set.</description>
          <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.899" lower_limit="0.7598" upper_limit="1.0643"/>
                    <measurement group_id="O2" value="1.060" lower_limit="0.8932" upper_limit="1.2572"/>
                    <measurement group_id="O3" value="0.956" lower_limit="0.8652" upper_limit="1.0559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.856" lower_limit="0.6935" upper_limit="1.0553"/>
                    <measurement group_id="O2" value="1.040" lower_limit="0.8514" upper_limit="1.2714"/>
                    <measurement group_id="O3" value="0.894" lower_limit="0.7650" upper_limit="1.0442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.849" lower_limit="0.5984" upper_limit="1.2044"/>
                    <measurement group_id="O2" value="0.972" lower_limit="0.7779" upper_limit="1.2151"/>
                    <measurement group_id="O3" value="0.779" lower_limit="0.5250" upper_limit="1.1572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.820" lower_limit="0.5729" upper_limit="1.1730"/>
                    <measurement group_id="O2" value="0.813" lower_limit="0.4480" upper_limit="1.4748"/>
                    <measurement group_id="O3" value="0.685" lower_limit="0.4652" upper_limit="1.0093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in NT-proBNP Levels Through Day 14</title>
        <description>NT-proBNP biomarker was used to assess the effect of serelaxinin on degree of cardiac wall stress and congestion. Geometric means of the ratio of post-Baseline values to baseline values of NT-proBNP was calculated by treatment for the full analysis set.</description>
        <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
        <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in NT-proBNP Levels Through Day 14</title>
          <description>NT-proBNP biomarker was used to assess the effect of serelaxinin on degree of cardiac wall stress and congestion. Geometric means of the ratio of post-Baseline values to baseline values of NT-proBNP was calculated by treatment for the full analysis set.</description>
          <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.585" lower_limit="0.4356" upper_limit="0.7865"/>
                    <measurement group_id="O2" value="0.646" lower_limit="0.5146" upper_limit="0.8115"/>
                    <measurement group_id="O3" value="0.673" lower_limit="0.5416" upper_limit="0.8363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.492" lower_limit="0.3421" upper_limit="0.7076"/>
                    <measurement group_id="O2" value="0.451" lower_limit="0.3271" upper_limit="0.6210"/>
                    <measurement group_id="O3" value="0.581" lower_limit="0.4410" upper_limit="0.7656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.388" lower_limit="0.2502" upper_limit="0.6028"/>
                    <measurement group_id="O2" value="0.386" lower_limit="0.2575" upper_limit="0.5796"/>
                    <measurement group_id="O3" value="0.526" lower_limit="0.3685" upper_limit="0.7503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.295" lower_limit="0.1649" upper_limit="0.5293"/>
                    <measurement group_id="O2" value="0.419" lower_limit="0.2621" upper_limit="0.6691"/>
                    <measurement group_id="O3" value="0.277" lower_limit="0.1875" upper_limit="0.4079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neutrophil Gelatinase-asc Lipocalin (NGAL) Levels Through Day 14</title>
        <description>Neutrophil gelatinase-asc lipocalin (NGAL) biomarker was used to assess the effect of serelaxin on kidney function. Geometric means of the ratio of post-Baseline values to baseline values of NGAL was calculated by treatment for the full analysis set.</description>
        <time_frame>Baseline, Day 1, Day 2, Day 5, Day 14</time_frame>
        <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Serelaxin 10 mcg/kg/Day</title>
            <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin 30 mcg/kg/Day</title>
            <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neutrophil Gelatinase-asc Lipocalin (NGAL) Levels Through Day 14</title>
          <description>Neutrophil gelatinase-asc lipocalin (NGAL) biomarker was used to assess the effect of serelaxin on kidney function. Geometric means of the ratio of post-Baseline values to baseline values of NGAL was calculated by treatment for the full analysis set.</description>
          <population>The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.011" lower_limit="0.8911" upper_limit="1.1478"/>
                    <measurement group_id="O2" value="1.083" lower_limit="0.9025" upper_limit="1.2996"/>
                    <measurement group_id="O3" value="1.054" lower_limit="0.9574" upper_limit="1.1613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.929" lower_limit="0.8443" upper_limit="1.0229"/>
                    <measurement group_id="O2" value="1.172" lower_limit="0.9994" upper_limit="1.3736"/>
                    <measurement group_id="O3" value="1.099" lower_limit="0.9866" upper_limit="1.2236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.129" lower_limit="1.0145" upper_limit="1.2560"/>
                    <measurement group_id="O2" value="1.238" lower_limit="1.0139" upper_limit="1.5114"/>
                    <measurement group_id="O3" value="1.135" lower_limit="1.0141" upper_limit="1.2698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.434" lower_limit="1.1760" upper_limit="1.7489"/>
                    <measurement group_id="O2" value="1.520" lower_limit="1.3214" upper_limit="1.7485"/>
                    <measurement group_id="O3" value="1.433" lower_limit="1.1793" upper_limit="1.7401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Serelaxin 10 mcg/kg/Day</title>
          <description>Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.</description>
        </group>
        <group group_id="E2">
          <title>Serelaxin 30 mcg/kg/Day</title>
          <description>Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>METASTASES TO LYMPH NODES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>METASTASES TO PERITONEUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFUSION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD PRESSURE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE SYSTOLIC DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>GENITAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-­site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 ­778 ­8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

